ClinicalTrials.Veeva

Menu

Pilot Study Evaluating the Therapeutic Effects of Passive Exposure Virtual Reality on Pain, Anxiety, Fatigue, and Well-being in Patients With Complex Palliative Care Needs. (EPURAVAS)

U

University Hospital, Strasbourg, France

Status

Not yet enrolling

Conditions

Palliative Care

Treatments

Behavioral: Passive Multisensory Virtual Reality Immersion via Head-Mounted Display (RVEP)
Behavioral: Transparent Augmented Reality with Real-World Video Feed Overlay (RVAT)

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The EPURAVAS "Pilot Study Using Augmented and Virtual Reality to Ease Suffering in Palliative Care" study is designed to investigate a non-medication treatment for complex symptoms in palliative care.

The purpose is to assess the clinical effectiveness of Virtual Reality (VR) exposure as a way to relieve the distressing symptoms experienced by individuals receiving specialized palliative care.

The study seeks to determine if immersive Passive Exposure Virtual Reality (RVEP) is more effective at providing a significant reduction in pain and anxiety, and a greater overall improvement in well-being and quality of life for patients in complex palliative situations, compared to a control virtual reality approach.

In the study, individuals are randomly assigned to one of two groups for a week:

  • Immersive VR: A headset completely surrounds the user in a calming, computer-generated world, aiming to deeply distract the mind from discomfort.
  • Control VR: A different headset allows the user to still see the real room while potentially having some virtual elements added. This acts as a comparison to measure the specific benefits of the deep immersion.

Participation involves daily 10-minute VR sessions for seven days. Throughout this time, physiological measurements are safely and continuously recorded using the VR headset and a connected watch. This collects objective information on how the body is reacting-things like brain activity, heart rate, and breathing-to scientifically determine the treatment's impact.

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient ≥ 18 years old
  • Hospitalized in the palliative care unit or followed by the mobile palliative care team of the Strasbourg University Hospitals
  • Estimated life expectancy > 1 month (Pronopall score calculated based on medical record data)
  • Affiliated with a social security scheme
  • Able to understand the objectives and risks of the trial
  • Able to understand and complete study questionnaires written in French
  • Reachable by phone or email for the entire duration of participation in the study

Exclusion criteria

  • Patient with a psychotic mental illness, followed and treated before the study, and not stabilized
  • Patient with a severe neurological disease, followed and treated before the study, and not stabilized
  • Patient with visual or auditory disorders, or motion sickness, present before the study, that could interfere with the use of virtual reality
  • Patient under legal protection or unable to express their consent

Trial design

40 participants in 2 patient groups

RVAT
Description:
The RVAT group serves as the control against which the experimental RVEP method is measured. Individuals in this group use a headset that is designed to be transparent or augmented, allowing them to remain aware of and oriented to their actual environment-the room they are in. While they may see some minimal virtual elements, there is no escape or full immersion into an alternative reality.
Treatment:
Behavioral: Transparent Augmented Reality with Real-World Video Feed Overlay (RVAT)
RVEP
Description:
Individuals in this group use a VR headset that creates a full sensory immersion, meaning the real world is completely blocked out. The experience involves being transported into calming, computer-generated environments, such as tranquil nature scenes. The goal of this full immersion is to achieve a deep, passive distraction that effectively shifts attention away from symptoms like pain and anxiety.
Treatment:
Behavioral: Passive Multisensory Virtual Reality Immersion via Head-Mounted Display (RVEP)

Trial contacts and locations

0

Loading...

Central trial contact

Laurent CALVEL, Pr; Daphné PRIEUR-DREVON, Dr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems